How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluticasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Flonase — Competitive Intelligence Brief

Flonase (fluticasone propionate) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled/intranasal corticosteroid. Area: Oncology.

marketed Inhaled/intranasal corticosteroid Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Flonase (fluticasone propionate) — GSK (GlaxoSmithKline).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Flonase TARGET	fluticasone propionate	GSK (GlaxoSmithKline)	marketed	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Fluticason	Fluticason	Creighton University	marketed		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor
Flixotide	Flixotide	Mundipharma Research Limited	marketed		Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

2026-03-03 — Flonase · FDA · approved · US · GSK (GlaxoSmithKline)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-08-26 — Flonase · 7500444*PED · Compound · US
2031-02-14 — Flonase · 10195375 · Formulation · US
2031-04-04 — Flonase · 12083270 · Method of Use · US
2031-08-14 — Flonase · 10195375*PED · Compound · US
2035-12-14 — Flonase · 10918816 · Formulation · US
2036-02-23 — Flonase · 11554229 · Method of Use · US
2036-06-14 — Flonase · 10918816*PED · Compound · US
2039-08-20 — Flonase · 11969544 · Formulation · US
2039-09-26 — Flonase · 11344685 · Formulation · US
2040-02-20 — Flonase · 11969544*PED · Compound · US
2040-03-26 — Flonase · 11344685*PED · Compound · US
2040-07-06 — Flonase · 11173259 · Formulation · US
2041-01-06 — Flonase · 11173259*PED · Compound · US

Sponsor landscape (Inhaled/intranasal corticosteroid class)

GSK (GlaxoSmithKline) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Flonase — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab